Home Featured Page 159

Featured

Latest

Psychedelic Policy Briefing: Week of June 29nd, 2026

A Country That Recalls Its Own Forgetting

Pα+ Psychedelic Bulletin #226: The Ethics of Psilocybin for Advanced Alzheimer’s; Veterans’ Views on Psychedelics

A Research Hypothesis, Not A Treatment Recommendation: Marcos Lago on the Viral Psilocybin for Alzheimer’s Case Report

Algernon Pharmaceuticals Announces Receipt of CDN $450K Cash Refund from Australian...

HAVN Life Provides Corporate Update

MindMed Collaborators Dose First Patient in Phase 1 Investigator-Initiated Trial of...

COMPASS Pathways to participate in upcoming Jefferies Innovation in Mental Health...

Bexson Biomedical Announces Renowned Scientist, Engineer and Inventor, Robert S. Langer...

PT357 – Dr. Hans Eriksson – Precision Psychiatry, Ketabon, and The...

Psyence Group Receives Phase IIa Clinical Trial Approval from the UK...

From Dendrites to Drug Discovery: An Interview with Dr. Alex Kwan

PsyBio Therapeutics Latest U.S. PCT (Non-Provisional) Patent Application Accepted

Algernon Pharmaceuticals Files for Orphan Designation with the U.S. FDA for...

EDITOR PICKS

Psychedelic Policy Briefing: Week of June 29nd, 2026

A Country That Recalls Its Own Forgetting

Pα+ Psychedelic Bulletin #226: The Ethics of Psilocybin for Advanced Alzheimer’s;...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Psychedelic Policy Briefing: Week of June 29nd, 2026

A Country That Recalls Its Own Forgetting

Pα+ Psychedelic Bulletin #226: The Ethics of Psilocybin for Advanced Alzheimer’s; Veterans’ Views on Psychedelics

A Research Hypothesis, Not A Treatment Recommendation: Marcos Lago on the Viral Psilocybin for Alzheimer’s Case Report

Psychedelics & Society

Algernon Pharmaceuticals Announces Receipt of CDN $450K Cash Refund from Australian...

HAVN Life Provides Corporate Update

MindMed Collaborators Dose First Patient in Phase 1 Investigator-Initiated Trial of...

COMPASS Pathways to participate in upcoming Jefferies Innovation in Mental Health...

Bexson Biomedical Announces Renowned Scientist, Engineer and Inventor, Robert S. Langer...

PT357 – Dr. Hans Eriksson – Precision Psychiatry, Ketabon, and The...

Psyence Group Receives Phase IIa Clinical Trial Approval from the UK...

From Dendrites to Drug Discovery: An Interview with Dr. Alex Kwan

PsyBio Therapeutics Latest U.S. PCT (Non-Provisional) Patent Application Accepted

Algernon Pharmaceuticals Files for Orphan Designation with the U.S. FDA for...

EDITOR PICKS

Psychedelic Policy Briefing: Week of June 29nd, 2026

A Country That Recalls Its Own Forgetting

Pα+ Psychedelic Bulletin #226: The Ethics of Psilocybin for Advanced Alzheimer’s;...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY